Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,698 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder
Interventions
Ketamine, Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Duloxetine on Norepinephrine

NCT00414323
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Escitalopram, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

NCT01250873
Conditions
Major Depressive Disorder
Interventions
LY2216684, Sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Major Depressive Disorder (MDD)
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
51
States / cities
Mesa, Arizona • Los Angeles, California • Oceanside, California + 42 more
Conditions
Bipolar Disorder, Bipolar Depression, Depression
Interventions
ziprasidone (Geodon), placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Chronic Affective Disorders, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Major Depressive Disorder
Interventions
TC-5214, Duloxetine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 22 more
Completed Not applicable Interventional Results available

Wake Therapy in the Treatment of Depression

NCT01431573
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Wake Therapy, light box, Lithium
Behavioral · Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
NeuroStar TMS
Device
Lead sponsor
Neuronetics
Other
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Baltimore, Maryland • Lincoln, Nebraska + 3 more
Conditions
Major Depressive Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 38 more
Conditions
Depression
Interventions
Memantine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis C, Major Depressive Disorder
Interventions
Exercise, Health Education
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Phoenix, Arizona • Okemos, Michigan • Omaha, Nebraska + 6 more
Completed Phase 2 Interventional Results available

AZD7268 Safety and Tolerability Study

NCT01020799
Conditions
Major Depressive Disorder
Interventions
AZD7268, Escitalopram, Placebo capsules, Placebo tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • San Diego, California + 14 more
Completed Phase 2Phase 3 Interventional Results available

A Study in Adult Patients With Major Depressive Disorder

NCT00795821
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Completed Phase 2 Interventional Results available

A Study of JNJ-61393215 in the Treatment of Depression

NCT04080752
Conditions
Major Depressive Disorder With Anxious Distress
Interventions
JNJ-61393215, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Garden Grove, California • Alpharetta, Georgia • Atlanta, Georgia + 6 more
Conditions
Major Depressive Disorder
Interventions
NEST-1 (NeoSync EEG Synchronized TMS), SHAM
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
22 Years to 65 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 15 more
Conditions
Major Depressive Disorder
Interventions
Zelquistinel
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Montclair, California + 27 more
Conditions
Major Depressive Disorder, Apathy
Interventions
Targeted Cognitive Training Intervention, General Cognitive Training Intervention
Behavioral
Lead sponsor
AdventHealth
Other
Eligibility
60 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Nicotine Dependence, Major Depressive Disorder
Interventions
Varenicline, BASC, Standard treatment
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
Conditions
Depressive Disorder, Major Depression, Depression, Depression, Unipolar
Interventions
Vortioxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Postpartum Depression
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, New York
Completed Not applicable Interventional Accepts healthy volunteers

Neural Components Underlying the Treatment of Adolescent Depression

NCT01717508
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Belmont, Massachusetts